Member Info for crumbs

It might be best you are not going to the proactive event mate as if you posted you cornered Cliff to ask some questions it would no doubt be twisted here into C7 grabbed Cliff in a headlock lol.... anyways hopefully tomorrow will bring us something proper to talk about as in real scancell news! Onwards :)

Yeah, a real pity you are unable to attend the proactive event...but understandable, all the best for Friday and like inanaco says anything of import is going to be in an RNS which is a very real possibility Tomorrow

Tomorrow ... Cliff informs me many of my questions to him will be answered tomorrow... so what might we expect?
SCIB1 IND update
SCIB2 CRUK progress and nano delivery update
TCR therapeutics update
BioNtech collab update
Modi1 progress to the clinic i.e tox testing update
Reason for head and neck replacing sarcomas as a modi1 trial target
Is project blueprint still alive? well is it...
Glycans update .. maybe a platform name?
Potential SCIBs progressing into the clinic in glioblastoma and pancreatic cancers ?
China... anything brewing there beyond green tea
SP will it ever see 10p again ( that one I let him off in not answering)

So if he really is going to answer many of those tomorrow could be interesting ....

To get involved with a domestic but the new staff indeed have not been brought in solely due to the BioNtech collab although Sam undoubtedly is involved in that area 'spearheading the new TCR therapeutics' being the clue there... something we very well may be hearing more about tomorrow...

BTW on project blueprint there seems to be some misunderstanding it was to be composed of scancells moditope in Modi3 and BioNtech/Genentechs mRNA vaccines ...it was not all about moditope

lol if scancell are relying on a proactive event that what a few dozen people will attend to raise placing funds then someone needs a head wobble :) no this is more an opportunity to give a much-needed update on all fronts of progress and indeed it seems that will be the case ... will it include anything about the constantly creeping need for more funds? maybe or maybe that will even get answered.. whatever the case it is great C7 will attend and at least get a canape for his troubles :)

I'm thinking the meaning is will SCIB2 use a nanovesicle delivery or electroporation.... It has already been answered it will be the nano delivery .... exactly what that will be and who's tech is yet to be revealed

If the sp could get infected by such a program nevermind sherbet lemons we would be minted!

We really could do with an updated picture and let's face it with scancells pipeline there is not one part of it that is standing still, apart from SCIB1!! Which due to that really does need an update even if it is a negative one we need to know when and where that trial is beginning as it has been far too long if the FDA isn't playing ball lets move it completely to the UK... I never fully bought the UK arm was suddenly decided on so Lindy could look at blood samples...

There is the potential of an RNS depending on what if anything new he will present considering since the last presentation he did was last Nov and we already know a lot has moved on since, we can but hope he gives an up to date picture ..I think the last one of these he did one of our BB guys recorded it?.. or was it RG who presented as Cliff was elsewhere and botski recorded it ? hmm I forget... possibly the 'left field news' comment one... news that we still are waiting on lol

Yes SCIB2 and now modi2 and what that means for the moditope platform with possible modi combos and new TCRs etc also be interesting to get an idea of is project blueprint in some form still alive?.... hopefully all of this will have been Cliffs holiday reading :)

And exactly no point in doing such events if they do not want to communicate the scancell story :)... the story is going to be further now than it was at the last such presentation... we have those all important key staff recruits...something has caused a target change in the modi1 trial... the BioNtech collab must be if not there already close to concluding the inital phase of discovering and characterising T cell receptors specific for citrullinated epitopes from vimentin and enolase.....what comes next there?...SCIB1 combo still not running what is happening!.. if FDA not forthcoming is there a plan to run it completely in the UK?.... will there be a proper unveiling of the Glycan(platform)... nano delivery of ImmunoBodies?....potential new ImmunoBodies heading to the clinic for glioblastoma and prostrate tatgets?.... there is much going on and it would be good if we get that communicated to us...

Well...he was 'overseas' but 'keeping a very close eye and involvement on all activities internal and external' so from that I took it as him being on holiday.

I'm glad to hear you're still up for Thursday as I doubt it will be a recorded event though maybe there will be a PDF presentation posted on the website... who knows! But the last such presentation was Nov of last year so we ought to expect some new news... I support all Chesters questions and indeed have asked as much in emails but you never get them answered to any satisfaction... surely though asking why head and neck has replaced sarcomas is something Cliff could give more information on... even if it were- because someone has asked us to... He has been on holiday the last couple of weeks and is back now so mustn't have been expecting any events he needed to present for but let us hope that is not the case now and that much progressive news is now expected ...

Yes all I'm pondering is the possible reason being trial funding reasons.... I'm sure we will find out in time

Just been thinking about it a bit due to it recently replacing sarcomas as a first modi1 trial target at such a late stage... and what Ray said about it being a project blueprint target and it is a cancer CRUK are really trying to get better treatments for.... I found this interesting trial at Southampton led by our old friend Professor Christian Ottensmeier...
https://www.southampton.ac.uk/news/2016/03/head-and-neck-cancer-trial.page
A collaboration by Cancer Research UK’s Centre for Drug Development (CDD) in partnership with biopharmaceutical company Amgen....
There are some results from it already and sadly it seems to be not a great success:
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.6068

Anyways just wondering if there is still a CRUK element to taking moditope forwards... it could be a cost-free route towards clinical validation ...I'm sure CRUK are still very interested in moditope and the potential offers as are others...

I wouldn't say it is the perfect trading share :) not at this stage, It does have the potential of being one the biggest multibaggers in AIM history a potential that gets bigger as the sp goes down but everything is dependent on outside forces and I would agree with you an element of luck of the stars aligning to get scancell to the next stage of its journey which hopefully ends with a respectable share of a future $100+ billion market.....onwards!

This article is very informative of the market scancell are in and the types of pharma deals done and on what therapies ...
https://www.genengnews.com/a-lists/top-10-immuno-oncology-collaborations-3/

Great article about China both entering the IO market with its own therapies and being a huge growing IO market itself ..

'chief executive of Shanghai Junshi Biosciences, during an interview last week. “Unlike drugs for chronic diseases, oncology treatment is very expensive, and hence efficacy is king. Whoever can demonstrate their drug has superior effectiveness and can meet the safety requirements will win.”'
https://www.scmp.com/business/china-business/article/3004850/can-cheaper-drugs-help-home-grown-labs-turn-table-foreign

Looks like a space for scancell that...

Well as you know... emerging market means the final value will not be known till it finally is.. however, if we go off the rates of cancer and presume Immunotherapies will eventually be the dominant treatments and capable of treating all cancers at all stages... $100s of billions ought to be the outcome... anyways its not just me predicting it!

'Analysts at Transparency Market Research (TMR) have predicted that the global market value of cancer immunotherapies will reach $124.88 billion by 2024, representing a compound annual growth rate of nearly 15% from 2016.

Included in the rising cancer immunotherapy figures are monoclonal antibodies, which according to the TMR report are widely liked for their effectiveness and reasonable price point, as well as immune checkpoint inhibitors, which the report speculates are likely to be a major growth area over the next few years.'

https://www.thepharmaletter.com/article/cancer-immunotherapy-market-to-be-worth-125-billion-by-2024

Yeah we have to try and get the bigger picture now some come out with so-called heard 'anecdotes' coming from AGMs like Lindy saying she has no clue what Karolinska is up to if anything with moditope only for them then to extend and broaden their research collaboration... duh.. likewise listening to actual recordings you hear how close Lindy and Sahin are how that predates the TCR collaboration and the amount of time and work Lindy has put into that collaboration only for 'the new TCR therapeutics' to arrive in an RNS ...you can bet the same is true of whatever the new nano delivery for ImmunoBody is too.... we only find stuff out later I honestly don't think even Chippers and Cliff are totally up to date with team science ...project blueprint showed us who is talking to team science same as Keith Flaherty was only too keen to get involved with others on the SCIB1 combo (though he might have forgot about it by now)) ...It only takes one very well connected scientist who has a say over their companies pipelines to 'get' what scancell have well in Sahin and Mellman we know of two already and I'm sure there are others yet to be revealed.